Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Oct 15;79(4):834-837.
doi: 10.1093/cid/ciae229.

The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?

Samuel L Aitken  1   2 , Virginia M Pierce  3   4 , Jason M Pogue  1   2 , Ellen G Kline  5 , Frank P Tverdek  6   7 , Ryan K Shields  5
Affiliations
Case Reports

The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?

Samuel L Aitken et al. Clin Infect Dis. .

Erratum in

Abstract

We report identification of 5 patients with infections caused by NDM-5-producing Escherichia coli harboring PBP3 mutations that showed reduced susceptibility to aztreonam-avibactam and cefiderocol. Durlobactam, a novel diazabicyclooctane β-lactamase inhibitor, demonstrated minimum inhibitory concentrations ranging from 0.5 to 2 µg/mL supporting future investigations into a potential role in clinical management.

Keywords: CMY; New Delhi metallo beta-lactamase; aztreonam; cefiderocol; zidebactam.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. S. L. A. reports serving on advisory boards for Entasis, Melinta, Shionogi, and Basilea and receiving consulting fees from GlaxoSmithKline. J. M. P. reports grant support from Merck and serving as a consultant for Merck, Shionogi, Entasis, Abbvie, and GSK. R. K. S. has served as a consultant for Merck, Melinta, Entasis, Abbvie, GlaxoSmithKline, Pfizer, Shionogi, Venatorx, and Roche, and has received investigator-initiated research funding from Merck, Melinta, Shionogi, Roche, and Venatorx. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

    1. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis 2023:ciad428. doi: 10.1093/cid/ciad428. - DOI - PubMed
    1. Alm RA, Johnstone MR, Lahiri SD. Characterization of Escherichia coli NDM isolates with decreased susceptibility to aztreonam/avibactam: role of a novel insertion in PBP3. J Antimicrob Chemother 2015; 70:1420–8. - PubMed
    1. Livermore DM, Mushtaq S, Vickers A, Woodford N. Activity of aztreonam/avibactam against metallo-beta-lactamase-producing Enterobacterales from the UK: impact of penicillin-binding protein-3 inserts and CMY-42 beta-lactamase in Escherichia coli. Int J Antimicrob Agents 2023; 61:106776. - PubMed
    1. Simner PJ, Bergman Y, Conzemius R, et al. An NDM-producing Escherichia coli clinical isolate exhibiting resistance to cefiderocol and the combination of ceftazidime-avibactam and aztreonam: another step toward pan-beta-lactam resistance. Open Forum Infect Dis 2023; 10:ofad276. - PMC - PubMed
    1. Timsit JF, Paul M, Shields RK, et al. Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies. Clin Infect Dis 2022; 75:1081–4. - PMC - PubMed

Publication types

MeSH terms